We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

AXA Diagnostics Srl

AXA Diagnostics offers a wide range of products, systems and services for laboratory specialists to help diagnose sev... read more Featured Products: More products

Download Mobile App





AXA Diagnostics Showcases SkyLAB752 ELISA Analyzer

By LabMedica International staff writers
Posted on 09 Feb 2017
Print article
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
Image: The SkyLAB752 ELISA analyzer (Photo courtesy of AXA Diagnostics).
AXA Diagnostics, part of Dasit Group S.p.A., which owns several companies in the fields of in-vitro diagnostics and life sciences, showcased updates and new applications of the SkyLAB752 system, its platform for ELISA and IFA automation, at MEDLAB 2017 held in Dubai, UAE from February 6-9, 2017.

Italy-based AXA Diagnostics develops, produces, and markets IVD reagents dedicated to autoimmunity diseases and instruments for the automation of all ELISA and IFA testing. The company’s SkyLAB752 fully automated analyzer can process up to 7 ELISA microplates or up to 28 IFA slides per each working session. The SkyLAB752 is equipped with two innovative dispensing systems that work simultaneously and independently, allowing ELISA and IFA assays to be processed simultaneously in the same working session.

The instrument’s architecture is designed to make it adaptable to processing even the greatest workloads. Designed to be easily integrated with a pre-analytical system, the flexibility of its working area allows the SkyLAB 752 to meet the wide requirements of each lab. At MEDLAB 2017, AXA Diagnostics also showcased reagent kits of its autoimmunity product line, which provides a wide choice of analytical techniques for performing both screening and confirmation testing, as well as allows patients’ follow up. This included ELISA reagent kits for the detection of specific auto-antibodies of the main classes (IgG, IgM and IgA) and their combinations, which are indicative of specific pathological conditions. It also included DOT BLOT reagent kits comprising numerous antigenic profiles for the confirmation of systemic autoimmune and organ specific diseases with several specific pathology markers.

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Male Fertility Rapid Test
SP-10
New
Carcinoembryonic Antigen Test
CEA Test

Print article

Channels

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Pathology

view channel
Image: The OmicsFootPrint AI tool could open doors to new discoveries (Photo courtesy of Mayo Clinic)

Revolutionary AI Tool Transforms Disease Visualization

Genes serve as the body's blueprint, while proteins execute the instructions within those blueprints to maintain cell function. Occasionally, alterations in these instructions—known as mutations—can interfere... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.